Added to YB: 2025-09-12
Pitch date: 2025-09-10
PTGX [bullish]
Protagonist Therapeutics, Inc.
+76.46%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Market Cap
$6.7B
Pitch Price
$57.81
Price Target
173.00 (+70%)
Dividend
N/A
EV/EBITDA
-43.75
P/E
-57.99
EV/Sales
81.96
Sector
Biotechnology
Category
growth
PTGX: A JNJ bond trading below face value with free call options attached!
PTGX: Oral IL-23 drug Icotrokinra (JNJ partner) showing superior efficacy vs injectables in psoriasis/UC, targeting $15B+ market. JNJ guides 2x consensus at $1.4B 2028 sales. 6-10% royalties could yield $400-900M annually. Rusfertide (Takeda) approval H2 2026, opt-out pays $400M. Pipeline includes oral IL-17 (LLY paid $2.4B for similar asset). Base case $67.5/share on approved drugs alone, current $58.
Read full article (18 min)